Medlea Srl

Our mission is to bring precision, personalization, and predictive intelligence to lung diagnostics and surgical planning. Through advanced 3D simulations and proprietary AI, Medlea enables clinicians to better understand lung structure and function—improving outcomes for patients with nodules, emphysema, fibrosis, COVID-related lesions, pleural effusion, and other complex conditions. Our core solutions: WeResp® – a professional-grade diagnostic software that leverages fractal AI to simulate bronchiolar architecture, ventilation, and perfusion from CT scans. FlowLeap – a cloud-native simulation tool that integrates fluid dynamics, elasticity modeling, and AI to optimize radiology workflows and contrast agent usage. Target users: Thoracic surgeons, pulmonologists, radiologists, ICU specialists, and clinical researchers working in public and private hospitals or outpatient settings. Clinical & international traction: We are actively collaborating with major hospitals in Europe and North America and are expanding our clinical validation and market entry. Regulatory & compliance: Medlea is on track for ISO 13485 certification and CE marking. We believe in a future where respiratory care is driven by digital intelligence and clinical insight—empowering healthcare professionals to act with confidence, precision, and foresight.